Here's what adults need to know about the recently approved RSV vaccines Arexvy and Abrysvo:
on May 31. Both approvals are for adults ages 60 and above, who are among the most vulnerable to the infection.
Awareness about the disease itself is another issue that may thwart the vaccine effort, as even some doctors mistakenly think of RSV as solely a pediatric danger, other experts said.via virus droplets, direct contact with the virus, or touching a surface with the virus on it, causing lower respiratory infections. It can occur in all age groups but can be especially dangerous in older adults and children younger than 5.
Leonard Friedland, MD, GSK’s vice president and director of scientific affairs and public health, vaccines, termed those results “exceptional” in an emailed response to questions. The vaccine reduced the risk of RSV-related lower respiratory tract disease with two or more symptoms by 66.7% and three or more symptoms by 85.7%. It was 62% effective against RSV-associated acute respiratory illness, which can lead to hospitalization.
With this immune response, “the antibodies produced against the F protein interfere with the virus’ ability to fuse and infect cells, enabling the immune system to fight off the virus better,” said Ann Falsey, MD, a professor of medicine at the University of Rochester School of Medicine and co-director of the University of Rochester Medical Center’s Vaccine and Treatment Evaluation Unit.
The expectation, Schaffner said, is that the panel will recommend the vaccine for those 60 and over or for those 65 and older. The CDC is not bound to follow the ACIP’s recommendations but typically does so.The CDC recommendation will more clearly spell out the starting age, experts expect. “I hope they recommend it for adults over 60, because that’s the population the trials were done in,” said Falsey, a longtime researcher of respiratory viruses and vaccines, including other RSV vaccines.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA advisors recommend AstraZeneca antibody to protect babies from RSVIf the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.
Read more »
FDA panel recommends injectable drug to prevent RSV in infantsThe monoclonal antibody shot would be given to babies during or before their first RSV season, as well as to high-risk children up to age 2 entering their second RSV season.
Read more »
US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapyThe U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.
Read more »
5 things to know for June 9: Trump, Air quality, Stocks, RSV, Ukraine | CNNHere are 5⃣ things to know today. 1⃣ Trump indicted 2⃣ Air quality set to improve 3⃣ S&P 500 in bull market territory 4⃣ RSV treatment for infants 5⃣ Ukraine dam collapse
Read more »
FDA panel endorses antibody therapy to protect against RSV in infantsIt is designed to be given in a single shot at birth or a baby’s first season of RSV.
Read more »